Biologics-In-A-Pill Firm PsiThera Launched With Series A $47.5m

 
• By Andrew McConaghie
  
The structure of Tumor Necrosis Factor (TNF) makes it a challenging target for small molecule drugs.
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from R&D

More from Scrip